Technical Analysis for JAGX - Jaguar Animal Health, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 1.07% | |
| Calm After Storm | Range Contraction | 1.07% | |
| Calm After Storm | Range Contraction | 0.08% | |
| NR7 | Range Contraction | 0.08% | |
| Narrow Range Bar | Range Contraction | 0.08% | |
| Inside Day | Range Contraction | 0.08% | |
| Gapped Up | Strength | 0.08% | |
| 20 DMA Resistance | Bearish | 2.07% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 21 hours ago |
| 10 DMA Resistance | about 21 hours ago |
| Outside Day | about 21 hours ago |
| Down 5% | about 21 hours ago |
| Down 3% | about 21 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2024
Jaguar Animal Health, Inc. Description
Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Gastrointestinal Animal Health Dog Gastroenterology Prescription Drugs Colitis Drug Products Diarrhea Gastrointestinal Tract Gastrointestinal Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.3 |
| 52 Week Low | 0.9 |
| Average Volume | 280,286 |
| 200-Day Moving Average | 4.26 |
| 50-Day Moving Average | 1.13 |
| 20-Day Moving Average | 1.03 |
| 10-Day Moving Average | 0.99 |
| Average True Range | 0.09 |
| RSI (14) | 42.20 |
| ADX | 14.67 |
| +DI | 17.89 |
| -DI | 20.27 |
| Chandelier Exit (Long, 3 ATRs) | 0.94 |
| Chandelier Exit (Short, 3 ATRs) | 1.16 |
| Upper Bollinger Bands | 1.15 |
| Lower Bollinger Band | 0.91 |
| Percent B (%b) | 0.29 |
| BandWidth | 23.31 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0016 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.11 | ||||
| Resistance 3 (R3) | 1.11 | 1.06 | 1.09 | ||
| Resistance 2 (R2) | 1.06 | 1.03 | 1.06 | 1.08 | |
| Resistance 1 (R1) | 1.02 | 1.00 | 1.04 | 1.02 | 1.08 |
| Pivot Point | 0.97 | 0.97 | 0.98 | 0.97 | 0.97 |
| Support 1 (S1) | 0.93 | 0.94 | 0.95 | 0.93 | 0.88 |
| Support 2 (S2) | 0.88 | 0.91 | 0.88 | 0.87 | |
| Support 3 (S3) | 0.84 | 0.88 | 0.87 | ||
| Support 4 (S4) | 0.84 |
